COVID-19: Vaccine variables and investment implications

CIBC Private Wealth US

In this interview hosted by Head of Equities Patricia Bannan, CFA, healthcare analysts Fred Weiss, CFA, and Mac Price, CFA, discuss the rapidly evolving landscape around the creation of a coronavirus vaccine. With 135 vaccine candidates in trials, including 15 already in human clinical trials, and the U.S. government’s Operation Warp Speed program helping to fast-track the vaccine development, manufacturing and distribution, experts have expressed optimism about a timeline for release in 2021. What do our analysts believe are the implications for investors?